Institute of Biotechnology and Department of Fundamental Microbiology, University of Lausanne, Lausanne, Switzerland.
Present address: Selexis SA, Plan-les-Ouates, Switzerland.
Biotechnol Bioeng. 2020 Feb;117(2):466-485. doi: 10.1002/bit.27200. Epub 2019 Nov 12.
The Chinese hamster ovary (CHO) cells used to produce biopharmaceutical proteins are known to contain type-C endogenous retrovirus (ERV) sequences in their genome and to release retroviral-like particles. Although evidence for their infectivity is missing, this has raised safety concerns. As the genomic origin of these particles remained unclear, we characterized type-C ERV elements at the genome, transcriptome, and viral particle RNA levels. We identified 173 type-C ERV sequences clustering into three functionally conserved groups. Transcripts from one type-C ERV group were full-length, with intact open reading frames, and cognate viral genome RNA was loaded into retroviral-like particles, suggesting that this ERV group may produce functional viruses. CRISPR-Cas9 genome editing was used to disrupt the gag gene of the expressed type-C ERV group. Comparison of CRISPR-derived mutations at the DNA and RNA level led to the identification of a single ERV as the main source of the release of RNA-loaded viral particles. Clones bearing a Gag loss-of-function mutation in this ERV showed a reduction of RNA-containing viral particle release down to detection limits, without compromising cell growth or therapeutic protein production. Overall, our study provides a strategy to mitigate potential viral particle contaminations resulting from ERVs during biopharmaceutical manufacturing.
用于生产生物制药蛋白的中国仓鼠卵巢 (CHO) 细胞已知在其基因组中含有 C 型内源性逆转录病毒 (ERV) 序列,并释放类逆转录病毒颗粒。尽管缺乏其感染性的证据,但这引起了安全性方面的担忧。由于这些颗粒的基因组起源尚不清楚,我们在基因组、转录组和病毒颗粒 RNA 水平上对 C 型 ERV 元件进行了表征。我们鉴定了 173 种 C 型 ERV 序列,它们聚类为三个功能保守的组。一组 C 型 ERV 的转录本是全长的,具有完整的开放阅读框,并且同源病毒基因组 RNA 被加载到类逆转录病毒颗粒中,表明该 ERV 组可能产生功能性病毒。使用 CRISPR-Cas9 基因组编辑来破坏表达的 C 型 ERV 组的 gag 基因。比较 DNA 和 RNA 水平的 CRISPR 衍生突变导致鉴定出一个 ERV 是 RNA 加载的病毒颗粒释放的主要来源。在该 ERV 中携带 Gag 功能丧失突变的克隆显示 RNA 含量的病毒颗粒释放减少到检测限以下,而不影响细胞生长或治疗性蛋白的生产。总体而言,我们的研究提供了一种策略,可以减轻生物制药制造过程中 ERV 导致的潜在病毒颗粒污染。